Tang Zhenning, Li Ling, Huang Xiaoying, Zhao Yinbing, Liu Qingyuan, Zhang Chaolin
Department of Surgical Oncology, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia, P. R. China.
Yinchuan First People\'s Hospital Department of Neurology Yinchuan China.
Recent Pat Anticancer Drug Discov. 2024 Jan 10. doi: 10.2174/0115748928258157231128103337.
Accumulated evidence suggest that tumor microenvironment (TME) plays a crucial role in breast cancer (BRCA) progression and therapeutic effects.
This study aimed to characterize immune-related BRCA subtypes in TME, and identify genes with prognostic value.
RNA sequencing profiles with corresponding clinical data from The Cancer Genome Atlas (TCGA) database of BRCA patients were downloaded to evaluate immune infiltration using the single-sample gene set enrichment (ssGAEA) algorithm. Further, BRCA was clustered according to immune infiltration status by consensus clustering analysis. Using Venn analysis, differentially expressed genes (DEGs) were overlapped to obtain candidate genes. Kaplan-Meier (K-M) analysis was performed to identify prognostic genes, and the results were verified in the GEO and METABRIC datasets. RT-qPCR was conducted to detect the mRNA expression of prognostic genes.
In the TCGA database, 3 immune-related BRCA subtypes were identified [cluster1 (C1), cluster2 (C2), and cluster3 (C2)]. The C2 subtype had better overall survival (OS) compared to the C1 subtype. Higher levels of immune markers and checkpoint protein were found in the C2 subtype than in others. By combining DEGs between BRCA and normal tissues, with the C1 and C2 subtypes associated with different OS, 25 BRCA candidate genes were identified. Among these, 8 genes were identified as prognostic genes for BRCA. RT-qPCR showed that the expressions of 2 genes were significantly elevated in BRCA tissues, while that of other genes were decreased.
Three BRCA subtypes were identified with the immune index, which may help design advanced treatment of BRCA. The data code used for the analysis in this article was available on GitHub (https://github.com/tangzhn/BRCA1.git).
越来越多的证据表明,肿瘤微环境(TME)在乳腺癌(BRCA)进展和治疗效果中起着关键作用。
本研究旨在表征TME中与免疫相关的BRCA亚型,并鉴定具有预后价值的基因。
从癌症基因组图谱(TCGA)数据库下载BRCA患者的RNA测序图谱及相应临床数据,使用单样本基因集富集(ssGAEA)算法评估免疫浸润。此外,通过一致性聚类分析根据免疫浸润状态对BRCA进行聚类。利用Venn分析重叠差异表达基因(DEG)以获得候选基因。进行Kaplan-Meier(K-M)分析以鉴定预后基因,并在GEO和METABRIC数据集中验证结果。进行RT-qPCR检测预后基因的mRNA表达。
在TCGA数据库中,鉴定出3种与免疫相关的BRCA亚型[簇1(C1)、簇2(C2)和簇3(C3)]。与C1亚型相比,C2亚型具有更好的总生存期(OS)。C2亚型中免疫标志物和检查点蛋白水平高于其他亚型。通过结合BRCA与正常组织之间的DEG,以及与不同OS相关的C1和C2亚型,鉴定出25个BRCA候选基因。其中,8个基因被鉴定为BRCA的预后基因。RT-qPCR显示,2个基因在BRCA组织中的表达显著升高,而其他基因的表达则降低。
通过免疫指标鉴定出三种BRCA亚型,这可能有助于设计BRCA的先进治疗方案。本文分析所用的数据代码可在GitHub(https://github.com/tangzhn/BRCA1.git)上获取。